How to Apply for a LUNGevity Grant

LUNGevity Awards for Translational Research

LUNGevity supports research in three tracks: career development, early detection, and targeted therapeutics.

Check back in December 2017 about which awards will be offered in 2018.

Career Development Awards

  • 3-year grants, totaling $300,000
  • Limit of one award per institution

2018 Letter of Intent Deadline:

Check back in December 2017

Career Development Awards

LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas.

Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission.

Funded projects are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.

Early Detection and Interception Award

LUNGevity Foundation is collaborating with Stand up to Cancer and the American Lung Association (via LUNG FORCE) on a new initiative, the SU2C-LUNGevity-American Lung Association Lung Cancer Interception Dream Team. The Thomas G. Labrecque Foundation is also investing in this collaboration. Delving into the newly emerging field of lung cancer interception, the team will embark on a 4-year research project to investigate early molecular or other changes that lead to cancer development. Early detection and interception are key elements for determining effective treatment options for patients and preventing the spread of cancer to other parts of the body, ultimately resulting in increased survival.

Therapeutics Awards

LUNGevity’s Therapeutics Awards for Translational Research support research projects directed at individualized treatments, including targeted therapeutics and immunotherapy, that will make a difference in the clinical treatment and survival of patients.